Complement Abnormality

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Complement Abnormality trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT04183101

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereb…

Sweden30 participantsStarted 2020-10-01

Treatment: Aliskiren, Enalapril

All recent trials (4 shown)

TerminatedPhase 2

NCT04725812

Complement Regulation to Undo Systemic Harm in Preeclampsia

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with pree…

United States2 participantsStarted 2021-09-13

Treatment: Eculizumab

CompletedPhase 1

NCT04103489

The Use of Eculizumab in HELLP Syndrome

This research study is being performed to see if women diagnosed with early preterm Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated…

United States3 participantsStarted 2021-02-23

Treatment: Eculizumab

Complement Abnormality

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

All recent trials (4 shown)

Complement Regulation to Undo Systemic Harm in Preeclampsia

The Use of Eculizumab in HELLP Syndrome

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

All recent trials (4 shown)

Complement Regulation to Undo Systemic Harm in Preeclampsia

The Use of Eculizumab in HELLP Syndrome

The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study